<DOC>
	<DOCNO>NCT02738801</DOCNO>
	<brief_summary>A multicenter randomize , double-blind , parallel group , placebo-controlled , exploratory phase IIa study subject Idiopathic Pulmonary Fibrosis ( IPF ) evaluate safety , tolerability , PK PD GLPG1690 . Male female subject age 40 year old screen determine eligibility . The screening period 4 week . At baseline , eligible subject randomize 3:1 ratio GLPG1690 match placebo administer 12 week . The subject visit study center screening , baseline , week 1 , 2 , 4 , 8 12 follow visit 2 week last administration study drug . Planned assessment : Adverse event reporting , clinical laboratory test , vital sign , physical examination , 12-Lead-ECG , PK blood sampling , biomarker blood/BALF sample , Spirometry , St George 's respiratory questionnaire , high-resolution compute tomography ( HRCT ) .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetic Pharmacodynamic Properties GLPG1690</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>1 . Subjects able willing sign IRB/IEC approve ICF 2 . Male female subject nonchildbearing potential age ≥ 40 year 3 . Subjects chest HRCT perform within 12 month prior screen 4 . Subjects IPF diagnose multidisciplinary team 5 . Subjects : a. FVC ≥50 % predict normal AND b. Diffusing capacity lung carbon monoxide ( DLCO ) ≥ 30 % predict normal correct hemoglobin 6 . Subjects force expiratory volume 1 second ( FEV1 ) /FVC ( TiffeneauPinelli index ) ratio ≥ 0.70 ( base prebronchodilator spirometry 7 . Subjects stable supportive care 8 . Subjects stable condition 1 . Subjects know hypersensitivity study drug ingredient 2 . Subjects history current immunosuppressive condition 3 . Subjects history malignancy within past 5 year 4. subject clinical significant abnormality ECG 5 . Subjects IPF exacerbation within 6 week prior screen 6 . Subjects low respiratory tract infection require antibiotic 4 week pre screen 7 . Smoking within 3 month prescreening 8. interstitial lung disease 9. history lung volume reduction surgery lung transplant 10. unstable cardiac pulmonary disease IPF within 6 month prescreening 11. subject abnormal liver function 12. subject abnormal renal function</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>GLPG1690</keyword>
	<keyword>Autotaxin</keyword>
</DOC>